Ki67 LABELLING INDEX: AN INDEPENDENT PREDICTOR OF PROGRESSION IN PROSTATE CANCER TREATED BY RADICAL PROSTATECTOMY
- 19 April 1996
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 178 (4) , 437-441
- https://doi.org/10.1002/(sici)1096-9896(199604)178:4<437::aid-path484>3.0.co;2-4
Abstract
The clinical course of prostate cancer is highly variable and cannot satisfactorily be predicted by histological criteria alone. Both tumour cell proliferation and neuroendocrine differentiation have been suggested as additional prognostic parameters, neuroendocrine differentiation being considered to enhance tumour cell proliferation. This study investigated the prognostic value of tumour cell proliferation [Ki67 labelling index (LI), MIB 1] and neuroendocrine differentiation and their relationship to each other. One hundred and thirty‐seven paraffin‐embedded radical prostatectomy specimens were examined. Neuroendocrine differentiation was found in 58 per cent of cases, but was not associated with pTN stage, Gleason score, Ki67 LI, or tumour progression. Ki67 LI was not significantly associated with pTN stage or with Gleason score. High grade (P=0·0005), advanced local stage (P=0·0004), positive lymph nodes (P=0·02), and high Ki67 LI (P=0·0203) were predictors of tumour progression if univariate analysis was performed, but Cox stepwise regression showed that only advanced local stage (P=0·0025) and Ki67 LI (P=0·0105) were independent predictors of tumour progression, the relative risk being 3·6 and 2·5, respectively. It is concluded that Ki67 is an important prognostic marker in prostate cancer with a potential for routine application.Keywords
This publication has 32 references indexed in Scilit:
- Proliferative activity in benign and neoplastic prostatic epitheliumThe Journal of Pathology, 1994
- Proliferating cell nuclear antigen and p53 expression as prognostic factors in T1‐2MO prostatic adenocarcinomaInternational Journal of Cancer, 1994
- Evaluation of Ki‐67 Monoclonal Antibody as Prognostic Indicator for Prostatic CarcinomaBritish Journal of Urology, 1993
- Proliferative activity determined by DNA flow cytometry and proliferating cell nuclear antigen (PCNA) immunohistochemistry as a prognostic factor in prostatic carcinomaThe Journal of Pathology, 1992
- P53 and Ki‐67 Immunoreactivity in Human Prostate Cancer and Benign HyperplasiaBritish Journal of Urology, 1992
- Relationship of proliferating cell nuclear antigen (PCNA) in prostatic carcinomas to various clinical parametersThe Prostate, 1992
- Pathological and clinical associations of Ki‐67 defined growth fractions in human prostatic carcinomaThe Prostate, 1992
- Relation of endocrine‐paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostateThe Prostate, 1991
- Growth fractions in human prostatic carcinoma determined by Ki‐67 immunostainingThe Journal of Pathology, 1988
- Prostatic adenocarcinoma evolving into carcinoid: selective effect of hormonal treatment?Journal of Clinical Pathology, 1986